 Michael Saccente
Concepts (110)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histoplasmosis | 2 | 2021 | 50 | 0.960 |
Why?
| | Acquired Immunodeficiency Syndrome | 3 | 2021 | 54 | 0.830 |
Why?
| | Lymphogranuloma Venereum | 1 | 2022 | 1 | 0.810 |
Why?
| | Proctocolitis | 1 | 2022 | 1 | 0.810 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2021 | 6 | 0.790 |
Why?
| | Pneumocystis carinii | 1 | 2021 | 4 | 0.790 |
Why?
| | beta-Glucans | 1 | 2021 | 23 | 0.780 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 53 | 0.760 |
Why?
| | Sweet Syndrome | 1 | 2021 | 10 | 0.750 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2021 | 20 | 0.740 |
Why?
| | Antifungal Agents | 4 | 2008 | 339 | 0.680 |
Why?
| | Citrus paradisi | 2 | 2008 | 10 | 0.540 |
Why?
| | Food-Drug Interactions | 2 | 2008 | 14 | 0.540 |
Why?
| | Itraconazole | 2 | 2008 | 40 | 0.540 |
Why?
| | HIV Infections | 3 | 2006 | 357 | 0.490 |
Why?
| | Blastomyces | 1 | 2010 | 31 | 0.350 |
Why?
| | Blastomycosis | 1 | 2010 | 62 | 0.350 |
Why?
| | Beverages | 2 | 2008 | 56 | 0.310 |
Why?
| | Candida | 1 | 2008 | 60 | 0.290 |
Why?
| | Arthritis, Infectious | 1 | 2008 | 45 | 0.290 |
Why?
| | Candidiasis | 1 | 2008 | 114 | 0.290 |
Why?
| | Anti-Retroviral Agents | 1 | 2006 | 14 | 0.280 |
Why?
| | Mycobacterium fortuitum | 1 | 2006 | 6 | 0.270 |
Why?
| | Joint Diseases | 1 | 2006 | 41 | 0.260 |
Why?
| | Tuberculosis | 2 | 2009 | 146 | 0.250 |
Why?
| | Patient Compliance | 1 | 2006 | 230 | 0.250 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 16 | 0.240 |
Why?
| | Prosthesis-Related Infections | 1 | 2006 | 105 | 0.230 |
Why?
| | Humans | 18 | 2022 | 50208 | 0.230 |
Why?
| | Amphotericin B | 1 | 2003 | 110 | 0.210 |
Why?
| | Male | 11 | 2022 | 25399 | 0.210 |
Why?
| | Glucans | 1 | 2021 | 10 | 0.200 |
Why?
| | Tuberculin Test | 1 | 2001 | 9 | 0.200 |
Why?
| | Homosexuality, Male | 1 | 2022 | 51 | 0.190 |
Why?
| | Adult | 9 | 2021 | 13324 | 0.190 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2000 | 15 | 0.180 |
Why?
| | Autoantibodies | 1 | 2021 | 116 | 0.180 |
Why?
| | Interferon-gamma | 1 | 2021 | 176 | 0.180 |
Why?
| | Cat-Scratch Disease | 1 | 1999 | 7 | 0.180 |
Why?
| | Liver Abscess | 1 | 1999 | 5 | 0.180 |
Why?
| | Retinitis | 1 | 1999 | 5 | 0.180 |
Why?
| | Meningitis | 1 | 1999 | 24 | 0.170 |
Why?
| | Optic Neuritis | 1 | 1999 | 21 | 0.170 |
Why?
| | Klebsiella Infections | 1 | 1999 | 12 | 0.170 |
Why?
| | Klebsiella pneumoniae | 1 | 1999 | 20 | 0.170 |
Why?
| | Facial Paralysis | 1 | 1999 | 24 | 0.170 |
Why?
| | Vancomycin Resistance | 1 | 2019 | 5 | 0.170 |
Why?
| | Endophthalmitis | 1 | 1999 | 25 | 0.170 |
Why?
| | Chronic Disease | 1 | 2022 | 571 | 0.170 |
Why?
| | Diabetes Complications | 1 | 1999 | 119 | 0.160 |
Why?
| | Vancomycin | 1 | 2019 | 81 | 0.160 |
Why?
| | Macrophages | 1 | 2019 | 363 | 0.140 |
Why?
| | Pharmaceutical Solutions | 2 | 2008 | 8 | 0.140 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 269 | 0.130 |
Why?
| | Area Under Curve | 2 | 2008 | 178 | 0.130 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 327 | 0.130 |
Why?
| | Cross-Over Studies | 2 | 2008 | 218 | 0.130 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 747 | 0.110 |
Why?
| | Female | 8 | 2010 | 26635 | 0.110 |
Why?
| | Ixodes | 1 | 2010 | 6 | 0.090 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2006 | 284 | 0.090 |
Why?
| | Lyme Disease | 1 | 2010 | 32 | 0.090 |
Why?
| | Borrelia burgdorferi | 1 | 2010 | 31 | 0.090 |
Why?
| | Retrospective Studies | 1 | 2021 | 6134 | 0.080 |
Why?
| | Pancreatic Diseases | 1 | 2009 | 15 | 0.080 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2009 | 40 | 0.080 |
Why?
| | Drug Resistance, Fungal | 1 | 2008 | 31 | 0.080 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2008 | 78 | 0.070 |
Why?
| | Administration, Oral | 1 | 2008 | 434 | 0.070 |
Why?
| | Sex Factors | 1 | 2008 | 697 | 0.060 |
Why?
| | Cyclodextrins | 1 | 2004 | 18 | 0.060 |
Why?
| | Critical Illness | 1 | 2006 | 288 | 0.060 |
Why?
| | Biological Availability | 1 | 2004 | 96 | 0.060 |
Why?
| | Middle Aged | 4 | 2009 | 12206 | 0.060 |
Why?
| | Burkholderia | 1 | 2002 | 11 | 0.050 |
Why?
| | Ultrasonics | 1 | 2002 | 31 | 0.050 |
Why?
| | Staphylococcus | 1 | 2002 | 35 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 195 | 0.050 |
Why?
| | Knee Prosthesis | 1 | 2002 | 51 | 0.050 |
Why?
| | Hip Prosthesis | 1 | 2002 | 71 | 0.050 |
Why?
| | Biofilms | 1 | 2002 | 181 | 0.050 |
Why?
| | Scotoma | 1 | 1999 | 7 | 0.040 |
Why?
| | Fundus Oculi | 1 | 1999 | 25 | 0.040 |
Why?
| | Arkansas | 2 | 2010 | 1985 | 0.040 |
Why?
| | Visual Field Tests | 1 | 1999 | 13 | 0.040 |
Why?
| | Lysostaphin | 1 | 2019 | 1 | 0.040 |
Why?
| | Multilocus Sequence Typing | 1 | 2019 | 14 | 0.040 |
Why?
| | Aged | 3 | 2019 | 9405 | 0.040 |
Why?
| | Daptomycin | 1 | 2019 | 29 | 0.040 |
Why?
| | Cell Wall | 1 | 2019 | 55 | 0.040 |
Why?
| | Prenatal Care | 1 | 2000 | 109 | 0.040 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2002 | 262 | 0.040 |
Why?
| | Bacteremia | 1 | 2019 | 92 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 270 | 0.040 |
Why?
| | Mass Screening | 1 | 2000 | 346 | 0.040 |
Why?
| | Incidence | 1 | 2000 | 1006 | 0.040 |
Why?
| | Mutation | 1 | 2019 | 1294 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2000 | 2766 | 0.030 |
Why?
| | Pregnancy | 1 | 2000 | 2604 | 0.030 |
Why?
| | Risk Factors | 1 | 2000 | 3629 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2009 | 34 | 0.020 |
Why?
| | HIV-1 | 1 | 2009 | 55 | 0.020 |
Why?
| | Adolescent | 1 | 2000 | 6390 | 0.020 |
Why?
| | Antitubercular Agents | 1 | 2009 | 106 | 0.020 |
Why?
| | Mycobacterium tuberculosis | 1 | 2009 | 285 | 0.020 |
Why?
| | Filtration | 1 | 2002 | 24 | 0.010 |
Why?
| | Colony Count, Microbial | 1 | 2002 | 66 | 0.010 |
Why?
| | Prospective Studies | 1 | 2002 | 2379 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2002 | 3154 | 0.010 |
Why?
| | Animals | 1 | 2010 | 13246 | 0.010 |
Why?
|
|
Saccente's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|